ArticleIndian journal of endocrinology and metabolism
Abnormalities of Endocrine Function Tests in COVID-19-Recovered Individuals.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-COVID-19 incidentally discovered adrenal findings (a CT-focused real-life study).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Impact of COVID-19 on endocrine system due to the widespread distribution of Angiotensin Converting Enzyme-2 (ACE2) receptors in different endocrine organs of the body has been shown in several studies. However, most of these studies were in the setting of acute COVID-19. The present study was planned to comprehensively evaluate endocrine abnormalities in COVID-19-recovered individuals. Methods: Eighty-three COVID-19-recovered individuals were recruited 8-20 weeks following the recovery. They were further stratified according to disease severity as defined by the Indian Council of Medical Research (ICMR). After recording their demographic and clinical details, an evaluation of inflammatory markers and different hypothalamic-pituitary axes involving thyroid, adrenal, gonadal and prolactin axes was carried out in them. Those who were on treatment for a previous endocrine disorder were not included in the study. Results: Eighty-three patients [33 (39.7%): mild and 50 (60.3%): moderate to severe COVID-19] were recruited after a period of 14.7 ± 3.4 weeks after recovery. Forty-four patients (53%) had some form of endocrine dysfunction. Central pituitary axis dysfunction was observed in 28 patients (33.7%), of which alterations in prolactin (20.4%) were the most common. Thyroid function abnormalities were noted in 25 (30.1%) patients, while gonadal dysfunction was detected in 14% of males and 6% of reproductive-aged females, respectively. Conclusion: Endocrine function test abnormalities were seen in a significant proportion of individuals even after a mean period of more than 3 months post-recovery from COVID-19. These have implications for the long-term endocrine and metabolic health of COVID-19-recovered individuals, besides alerting physicians to interpret endocrine function tests with caution after recovery from acute COVID-19 illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.